CD8A and hepatocellular carcinoma: Meanwhile, we found that the post-RFA serum of recurrent HCC patients could reduce population of CD8 Tem and CD8 Teff, and the CD161 expression in CD4 Teff, CD4 Tnaive, CD8 Tem, CD8Teff, and CD8 Tnaive.